My letter to Mr. Paul Frieman:
hastily done, and full of anxiety...
Mr. Paul Frieman,
I've been an NTII shareholder for the last 3 years, and though I've been relatively assured about my investment up to this point, I'm now concerned about the company's inability to secure any kind of funding for the past several months.
Based on the Press release issued today, this would be the last Q the company would be able to fund its ongoing operations, and since we do not have a conference call this time around, I thought about sending an e-mail. My question is simply,
#1. Back in May 1998, the company was looking for only $5 million, and to get back onto the NAzdaq, with a drug like memantine in advanced Phase II trials, why has it been so difficult to seek financing ?
#2. Even if it means significantly diluting shareholder interest, wouldn't that be a better alternative than finally stopping or pausing operations ? I mean what other choice do we have in the absence of funding ?
#3. I've been heraing the same statements regarding financing for quite some time; The agreement with Merz aside, is there something tangible in the works at this point ?
I hope you understand that I'm not a high risk investor and was drawn into NTI before its financial woes started, I've a significant holding in the company, so my patience is running thin at this time, especially since I might not be as informed as the rest of the shareholders and certainly not privy to the thoughts of the management on these issues.
thank you for an informative reply
sincerely
_________________ |
